ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Heterogeneity in primary gastrointestinal DLBCL: from clinical management to molecular mechanisms and treatment strategies.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), with approximately 30%-40% of cases occurring in extranodal organs. Primary gastrointestinal diffuse large B cell lymphoma (PGI-DLBCL) is a predominant subtype of extranodal lymphoma, accounting for 40%-50% of extranodal DLBCL cases. However, due to its location of onset in the gastrointestinal tract, it is different from cancer of epithelial or primary intranodal DLBCL or other extranodal DLBCL. The patients with PGI-DLBCL are often first diagnosed in the department of gastroenterology and gastrointestinal surgery. These patients are prone to develop bulky masses and lead to severe gastrointestinal complications. The heterogeneity of PGI-DLBCL is not only reflected in the differences in gene mutation profiles and tumor microenvironment but is also closely related to the diversity of clinical manifestations, varied treatment responses, and complex prognostic stratification. Currently, the clinicopathological characteristics and molecular genetics of these patients are not fully understood, which will lead to the clinical management difficulties and challenges. This review provides a relatively comprehensive analysis about the heterogeneity of PGI-DLBCL from four perspectives: aggressive growth features, pathological features, molecular genetic characteristics, and treatments.
Indexed as
Identifiers
41917339What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.